Q&A with Matthew Scholz: How DGI’s technology expands and enhances the Immusoft platform

Posted on by Mike Wussow

On March 8, one of the first companies we funded, Immusoft, announced it has acquired Discovery Genomics, Inc., bringing new expertise and technologies to its therapeutic platform. We asked Matthew Scholz, CEO, if he could share the story behind the acquisition and what it means for Immusoft going forward.